**FDA Approved Indications**

- Adjuvant treatment for node-positive breast cancer

- Treatment of metastatic breast cancer after failure of combination chemotherapy that included an anthracycline

- Treatment of metastatic breast cancer that relapsed within six months of adjuvant chemotherapy that included an anthracycline

- Treatment of AIDS-related Kaposi sarcoma (second line)

- Treatment of non-small cell lung cancer in combination therapy with cisplatin in patients who are not candidates for surgery and/or radiation therapy

- Treatment of ovarian cancer in combination with cisplatin

- Subsequent therapy for the treatment of advanced ovarian cancer in combination with cisplatin

**Non-FDA Approved Indications**

- Treatment of metastatic or advanced bladder cancer in combination therapy with gemcitabine

- Treatment of advanced cervical cancer in combination with topotecan, bevacizumab, and/or cisplatin

- Preoperative management of esophageal and gastric cancers in combination with carboplatin and radiation therapy

- Treatment of advanced head and neck cancer in combination with cisplatin

- Neoadjuvant treatment in penile cancer with bulky regional lymph node metastases

- Treating relapsed or refractory small-cell lung cancer

- Treatment of advanced or unresectable angiosarcoma

- Treatment of relapsed or refractory testicular germ cell tumors in combination with gemcitabine and oxaliplatin or ifosfamide and cisplatin

- Treatment of advanced thymoma/thymic carcinoma in combination with carboplatin

- Treatment of unknown primary adenocarcinoma in combination with carboplatin and/or etoposide

- Treatment of endometrial carcinoma

- Treatment of metastatic or unresectable esophageal cancer

- Treatment of metastatic or unresectable gastric cancer

- Treatment of melanoma

- Treatment of anaplastic thyroid cancer